In October, LGND will be at a conference on insulin resistance:
IBC's Second International Conference on
Insulin Resistance
October 6-7, 1997 ú Ritz-Carlton Hotel ú Philadelphia, PA
REGULATION OF THE MECHANISTIC ACTIONS OF INSULIN
ú PC-1 as a Regulator of Insulin Resistance ú Normalizing Insulin Action ú Role of
Leptin on In Vivo Insulin Action ú Role of TNF-[alpha] in Insulin Resistance and
Obesity ú Free Fatty Acids in Insulin Resistance ú Role of the Sympathetic Nervous
System in Insulin Resistance ú IRS-1 Protein Family in Insulin Signaling ú Design of
Molecular Treatments for NIDDM
GLUCOSE METABOLISM
ú PI3K in Intracellular Membranes ú GLUT4 Glucose Transporter ú CP-91149
Inhibitor ú Reduced plasma glucose concentration in vivo ú Reduced hepatic
glycogen breakdown
PHARMACOLOGIC INTERVENTION
ú Growth Hormone Antagonists in Insulin Resistance ú RXR-Specific Ligands as
Insulin Sensitizers ú Amylin and Metabolic Control ú Promotion of glucose tolerance
ú Inhibition of glucagon secretion ú Insulin Resistant Animal Models ú [beta]-3
Receptor Agonist in the Treatment of NIDDM ú Combinatorial Chemistry as an
Optimization Tool
INDUSTRY UPDATES FROM
ú Amylin Pharmaceuticals ú Bayer Corp. ú Eli Lilly & Co. ú Ergo Science ú Exocell,
Inc. ú Hoffman-LaRoche ú Hoechst Marion Roussel ú Ligand Pharmaceuticals
ú Novo Nordisk ú Pfizer ú Sensus Corp. ú SmithKline Beecham ú Texas
Biotechnology, Inc.
Post-Conference Workshop ú Tuesday, October 7, 1997
Advances in Drug Discovery and
Development for Diabetic Complications
ú Genetics of Diabetic Nephropathy ú Genetic mapping studies ú Locating and
identifying new NIDDM-nephropathy genes ú BRl 49653 Anti-Diabetic Agent
ú Prevention of morphological changes in the pancreas ú Prevention of islet
[beta]-cell proliferation ú Amadori Adducts and TGF-[beta] in Diabetic
Nephropathy ú Advanced Glycosylation Endproducts ú Proteins ú Lipids ú DNA
ú Free amino groups
CHAIRPERSONS:
DISTINGUISHED FACULTY:
Tommy A. Brock, Ph.D.,
Senior Director,
Texas Biotechnology Corporation
Ira D. Goldfine, M.D.,
Professor of Medicine and
Physiology,
Director of Diabetes and
Endocrinology Research,
Mount Zion Medical Center
Mads Krogsgaard Thomsen,
Ph.D., DVM,
Corporate Vice President,
Health Care Discovery,
Novo Nordisk, Denmark
Anthony J. Shuker, Ph.D.,
Senior Organic Chemist,
Lilly Research Laboratories
Morris J. Birnbaum, M.D., Ph.D.,
Howard Hughes Medical Institute,
Professor, Department of Internal
Medicine,
University of Pennsylvania School
of Medicine
Esper Boel, Ph.D.,
Director of Molecular Genetics,
Novo Nordisk, Denmark
Donald W. Bowden, Ph.D.,
Professor of Biochemistry and
Internal Medicine,
Bowman Gray School of Medicine
of Wake Forest University
Truman R. Brown, Ph.D.,
Chairman,
Department of NMR and Medical
Spectroscopy,
Fox Chase Cancer Center
Robin Buckingham, Ph.D.,
Assistant Director,
Department of Vascular Biology,
SmithKline Beecham
Pharmaceuticals, United
Kingdom
Anthony H. Cincotta, Ph.D.,
Chief Scientific Officer and
Executive Vice President,
Ergo Science
Kevin B. Clairmont, Ph.D.,
Senior Research Scientist,
Metabolic Disorders Research,
Bayer Corporation
Margo P. Cohen, M.D.,
Scientific Director,
Exocell, Inc.
Jamie Dananberg, M.D.,
Clinical Research Physician,
Lilly Research Laboratories
G”khan S. Hotamisligil, M.D.,
Ph.D.,
Assistant Professor,
Harvard School of Public Health
Barbara B. Kahn, M.D.,
Chief, Diabetes Unit,
Beth Israel Deaconess Medical
Center,
Associate Professor of Medicine,
Harvard Medical School
Jarema Kochan, Ph.D.,
Research Leader,
Department of Metabolic Diseases,
Hoffman-LaRoche
Gnter Mller, Ph.D.,
Research Scientist,
Department of Metabolic Diseases
Research,
Hoechst Marion Roussel
Pharmaceuticals, Germany
Luciano Rossetti, M.D.,
Professor of Medicine,
Albert Einstein College of
Medicine
John A. Scarlett, M.D.,
President & CEO,
Sensus Corporation
Gerald I. Shulman, M.D., Ph.D.,
Professor of Internal Medicine and
Cellular and Molecular Physiology,
Yale University School of
Medicine
Ira G. Schulman, Ph.D.,
Research Scientist,
Department of Retinoid Research,
Ligand Pharmaceuticals
Judith L. Treadway, Ph.D.,
Senior Research Investigator,
Department of Cardiovascular and
Metabolic Diseases,
Central Research Division,
Pfizer, Inc.
Morris F. White, Ph.D.,
Investigator,
Cellular and Molecular Physiology,
Joslin Diabetes Center,
Associate Professor of Medicine,
Harvard Medical School
Andrew Young, Ph.D.,
Vice President of Physiology,
Amylin Pharmaceuticals
Details can be found at:
ibcusa.com |
